Author Affiliations: Academic Respiratory Unit, School of Clinical Sciences, University of Bristol, Bristol, England.
Malignant pleural effusion affects more than 150 000 patients per year in the United States, and its prevalence continues to increase.1 A malignant pleural effusion usually signifies advanced metastatic disease and is associated with a poor prognosis with median survival between 3 and 12 months, depending on the primary site.2 Lung cancer accounts for more than a third of cases of malignant effusion, with a life expectancy of less than 4 months.3,4
Maskell NA. Treatment Options for Malignant Pleural Effusions: Patient Preference Does Matter. JAMA. 2012;307(22):2432–2433. doi:10.1001/jama.2012.5543
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: